T. Rowe Price Associates
CTKB icon

T. Rowe Price Associates’s Cytek Biosciences CTKB Stock Holding History

T. Rowe Price Associates’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$351K Buy
80,142
+10,349
+15% +$48.9K ﹤0.01% 2610
2025
Q4 		$353K Buy
69,793
+7,658
+12% +$35.6K ﹤0.01% 2560
2025
Q3 		$216K Buy
62,135
+5,314
+9% +$19.9K ﹤0.01% 2763
2025
Q2 		$194K Buy
56,821
+3,484
+7% +$11.6K ﹤0.01% 2726
2025
Q1 		$214K Buy
53,337
+6,148
+13% +$31.9K ﹤0.01% 2601
2024
Q4 		$307K Buy
47,189
+7,686
+19% +$45.8K ﹤0.01% 2497
2024
Q3 		$219K Buy
39,503
+1,176
+3% +$6.67K ﹤0.01% 2621
2024
Q2 		$214K Buy
38,327
+3,662
+11% +$22K ﹤0.01% 2567
2024
Q1 		$233K Buy
34,665
+3,987
+13% +$31.5K ﹤0.01% 2542
2023
Q4 		$280K Buy
30,678
+2,630
+9% +$16.6K ﹤0.01% 2410
2023
Q3 		$155K Buy
28,048
+3,304
+13% +$26.5K ﹤0.01% 2569
2023
Q2 		$212K Buy
24,744
+3,210
+15% +$28.8K ﹤0.01% 2509
2023
Q1 		$198K Buy
21,534
+1,558
+8% +$16.8K ﹤0.01% 2534
2022
Q4 		$204K Buy
19,976
+1,573
+9% +$21.1K ﹤0.01% 2526
2022
Q3 		$271K Buy
18,403
+7,508
+69% +$97.5K ﹤0.01% 2423
2022
Q2 		$117K Buy
+10,895
New +$108K ﹤0.01% 2725

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates's CTKB Position: Q1 2026 in Review

T. Rowe Price Associates increased its Cytek Biosciences (CTKB) stake by 15% in Q1 2026, buying an estimated $48.9K and bringing the position to 80,142 shares worth $351K. The position accounts for ﹤0.01% of the portfolio, ranked #2610.

T. Rowe Price Associates first reported a position in CTKB in Q2 2022 and has held it in 16 quarters since. The position peaked at $353K in Q4 2025. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • T. Rowe Price Associates held 80,142 shares of Cytek Biosciences worth $351K as of Q1 2026.
  • T. Rowe Price Associates bought 10,349 Cytek Biosciences shares in Q1 2026, an estimated $48.9K.
  • Cytek Biosciences made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2610 holding.
  • T. Rowe Price Associates first reported a position in Cytek Biosciences in Q2 2022 and has held it in 16 quarters since.
  • T. Rowe Price Associates's Cytek Biosciences position peaked at $353K in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.